About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Proteomics Research of Osteosarcoma

Clinicaltrials.gov identifier NCT03932058

Recruitment Status Recruiting

First Posted April 30, 2019

Last update posted May 2, 2019

Study Description

Brief summary:

Retrospectively collected 400 cases of clinical data and pathological paraffin specimens of osteosarcoma, chondrosarcoma (control) and endogenous chondroma (control) in our hospital from 2008 to 2014, combined with high-pressure cycle-satellite scanning mass spectrometry (PCT-SWATH) Molecular typing of osteosarcoma and prediction of targeted therapy, the establishment of a new molecular classification based on proteomics for osteosarcoma to predict the chemotherapy response and recurrence risk of osteosarcoma. Clinical osteosarcoma patients include as many types as possible: pre-chemotherapy, post-chemotherapy, recurrence, and metastasis. The study did not involve vulnerable groups, and it was taken as a postoperative wax specimen for patients, which had no health, life and other effects on patients. Study application exemption from informed consent.

  • Condition or Disease:Osteosarcoma
  • Intervention/Treatment: Drug: Chemotherapy
  • Phase: N/A
Detailed Description


Study Design
  • Study Type: Observational
  • Estimated Enrollment: 400 participants
  • Observational Model: Case-Control
  • Time Perspective: Retrospective
  • Official Title: Establishment of New Molecular Prototyping Based on Proteomics for Predicting Osteosarcoma Chemotherapy Response and Risk of Recurrence
  • Actual Study Start Date: September 2018
  • Estimated Primary Completion Date: September 2019
  • Estimated Study Completion Date: September 2020
Groups and Cohorts
Groups/Cohorts Intervention/treatment
: osteosarcoma
Drug: Chemotherapy
all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
Outcome Measures
  • Primary Outcome Measures: 1. proteomics changes [ Time Frame: 2 years ]
    Study of changes in proteomes in tumor cells by high-throughput proteomics analysis
Eligibility Criteria
  • Ages Eligible for Study: (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Probability Sample
  • Study Population: primary care clinic

Inclusion Criteria:

- all osteosarcoma patients in our hospital

- received Methotrexate+Doxorubicin+Cisplatin protocol chemotherapy

Exclusion Criteria:

- non-chemotherapy patients

- bio-specimen not completed

Contacts and Locations

Contact: zhan Wang, Dr. +8618758586092 wangzhan515@yahoo.com

Contact: Xiaobo Yan +8613588153306 yanxiaobo82@gmail.com


China, Zhejiang
2nd Affiliated Hospital of Zhejiang University

Sponsors and Collaborators

Second Affiliated Hospital, School of Medicine, Zhejiang University


Principal Investigator: zhaoming Ye, Prof. 2nd Affiliated Hospital Of Zhejiang University

More Information
  • Responsible Party: Second Affiliated Hospital, School of Medicine, Zhejiang University
  • ClinicalTrials.gov Identifier: NCT03932058 History of Changes
  • Other Study ID Numbers: PR-OS-001
  • First Posted: April 30, 2019 Key Record Dates
  • Last Update Posted: May 2, 2019
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Osteosarcoma